Trial Profile
Retrospective study of age-related macular degeneration patients previously treated with bevacizumab and switched to ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Bevacizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 04 Feb 2016 New trial record